The early potential candidates for the next Tax Loss Selling Recovery Portfolio are few and far between.
Here's what Jim Cramer expects to hear from GSK at this week's investor meeting.
Clearside Biomedical and Omeros Corp. both have promising products that should win regulatory approval in the coming months.
And I was right, and the cynics were wrong. Here's why that matters more than ever now.
My recommendation is not for the shy, timid, or new trader.
Here's where traders could probe the long side of JNJ.
While it's tempting to take on a long-side trade here, I don't see a good reason.
This drugmaker is making a historic upside breakout. Let's check the charts.
PRGO traded up sharply Thursday -- and may not be done.
Here's what traders should consider doing now.